Month: June 2020

Study with JNJ-40411813 (ADX71149) will treat first epilepsy patients in early 2021Geneva, Switzerland, June 16, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), will advance into a Phase 2a proof of concept study in patients with epilepsy. The multi-center study is scheduled to begin dosing patients in the United States early 2021. Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, is responsible for the clinical development and commercialization of JNJ-40411813 (ADX71149) under the terms of a licensing agreement with Addex.Glutamate...

North American feasibility study demonstrated the utility, safety and efficacy of the alfapump in the management of patients with recurrent and refractory ascitesGHENT, Belgium, June 16, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that the results of MOSAIC, the North American feasibility study of the alfapump in recurrent and refractory liver ascites, have been published in Liver Transplantation, the peer-reviewed publication of the American Association for the Study of Liver Diseases.The publication entitled “Improvement in Quality of Life and Decrease in Large-Volume Paracentesis Requirements with the Automated Low-Flow Ascites Pump” concluded that the alfapump appears to be a promising...

WISEKEY APPOINTS RICHARD VENIA AS U.S. SALES DIRECTOR Geneva, Switzerland, June 16, 2020: WISeKey International Holding Ltd (“WISeKey“, SIX: WIHN, NASDAQ: WKEY), a leading cybersecurity and IoT company announced today that it has appointed Richard Venia as Sales Director for U.S.Mr. Venia is an international business professional with over 15 years of experience in Semiconductors and other high-tech industries. While most of Mr. Venia’s career has been in Silicon Valley and Hollywood, he has also worked in Japan.In the realm of Cybersecurity, his professional experience includes:Distribution Technology and Media Security Lab Manager at The Walt Disney Studios, where he was responsible for investigating circumvention technologies in support of content protection and antipiracy initiativesBusiness Development Manager at Atmel Corporation...

WISEKEY TO HOST A VIRTUAL INVESTOR FIRESIDE CHATON FRIDAY, JUNE 19TH  Geneva, Switzerland, June 16, 2020: WISeKey International Holding Ltd (“WISeKey“, SIX: WIHN, NASDAQ: WKEY), a leading cybersecurity and IoT company announced today that it will hold a virtual investor fireside chat on Friday, June 19th at 11:00 am ET (5:00 pm CET).During a live video fireside chat, WISeKey’s CEO, Carlos Moreira and CFO Peter Ward, will be discussing recent business developments and growth initiatives.  Immediately following the prepared remarks, management will participate in an interactive Q&A session with interested parties, allowing participants to type in questions and receive live responses. A webcast replay will be available two hours following the live fireside chat on the “Investor Relations” section of WISeKey’s website http://wisekey.com/investors/.To...

The shares in Borregaard ASA will be traded ex-dividend of NOK 2.30 per share as from today, 16 June 2020.Borregaard ASASarpsborg, 16 June 2020Contact:Lotte Kvinlaug, Investor Relations Officer, +47 922 86 909This information is subject to the disclosure requirements pursuant to Section 5 -12 of the Norwegian Securities Trading Act.  

Schibsted ASA has on 15 June 2020 sold 2,186 treasury B-shares to participants in the Employee Share Saving Plan at a price of NOK 213.40 per B-share (the price is set according to standard procedure for the program two days after the release of Schibsted’s Q1 2020 report, the closing price 08 May 2020). The shares will be transferred to the participants in the coming days. The transaction is related to the first enrollment window in the Employee Share Saving Plan for 2020 for non-Norwegian employees which closed in February 2020, and based on savings made during March 2020.Shares sold and transferred to primary insider employees are disclosed in the attachment.After these transactions, Schibsted ASA holds 3,543,657 treasury A-shares and 1,356,851 treasury B-shares.For more information on the employee share saving plan please refer to...

Bollène le 16 juin 2020, 07h00 (CET)Communiqué de pressePour diffusion immédiateMise à disposition duDocument d’Enregistrement Universel 2019Egide annonce que son Document d’Enregistrement Universel 2019 a été déposé auprès de l’Autorité des Marchés Financiers (AMF) en date du 15 juin 2020.Ce document est disponible sur le site Internet de l’AMF, http://www.amf-france.org , ainsi que sur le site Internet d’Egide, www.egide-group.com .Les documents suivants, diffusés au titre de l’article 222-3 du Règlement Général de l’AMF concernant l’information réglementée, et ceux prévus à l’article R.225-83 du Code de commerce, sont intégrés dans le Document d’Enregistrement Universel 2019.Il comprend :a) Le rapport financier annuel 2019, dont :·les comptes consolidés ;·les comptes sociaux ;·le rapport de gestion du Conseil d’Administration incluant...

Многоцентровое рандомизированное двойное слепое плацебо-контролируемое клиническое исследование фазы 2/3 opaganib для пациентов с тяжелой формой COVID-19 планируется провести в России и других европейских и других странах.—Параллельно в США начато клиническое исследование opaganib для пациентов с тяжелой формой COVID-19 в фазе 2а.ТЕЛЬ-АВИВ, Израиль и Ралей, Северная Каролина, June 16, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) («RedHill» или «Company»), специализированная биофармацевтическая компания, сегодня объявила о том, что она подала заявку на клинические испытания (CTA) в Министерство здравоохранения Российской Федерации для клинического исследования фазы 2/3 по оценке opaganib (Yeliva®, ABC294640)1 у пациентов, госпитализированных с тяжелой инфекцией SARS-CoV-2 (причина возникновения COVID -19) и...

MISSISSAUGA, Ontario, June 15, 2020 (GLOBE NEWSWIRE) — Smart Employee Benefits Inc. (“SEB” or the “Company”) (TSXV: SEB) today reports its financial results for the first quarter of 2020.States John McKimm, President/CEO/CIO of Smart Employee Benefits Inc.:“Adjusted EBITDA and EBITDA improved significantly for the first quarter, 2020 over the comparable period the previous year.  The gross margin percentage quarter over quarter declined 1.2%. Operating costs reduction initiatives led to the year over year improvement of over $1.089M in cost structure, which is expected to be over $4.0M annually.EBITDA improved by $0.937M in the first quarter to a negative $0.072M from a negative $1.009M.  Adjusted EBITDA for the year improved by $0.870M to a negative $0.056M from a negative $0.926M. The improvement is the result of cost reduction...

HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the pricing of its previously announced underwritten public offering. Celldex is offering 13,377,926 shares of its common stock, par value $0.001 per share, at a price to the public of $9.75 per share. In connection with the offering, Celldex has also granted the underwriter a 30-day option to purchase up to an additional 2,006,688 shares of common stock offered in the public offering, at the same public offering price per share less underwriting discounts and commissions.Cantor Fitzgerald & Co. is acting as the sole book running manager for the offering. H.C. Wainwright & Co. is acting as co-manager for the offering.The Company expects to receive gross proceeds from the offering, excluding...